Efficacy and Safety of a Novel Extract of Amanita Muscaria in the Treatment of Major Depressive Disorder

This scientific article was published in the journal "Journal of Psychopharmacology" in 2022.


  • Dr. Paul Stamets, founder of MycoMedica, a company that researches and develops pharmaceutical products based on mushrooms.
  • Dr. James Fadiman, a psychiatrist known for his research on psychedelic drugs.
  • Dr. Michael Smith, a neuroscientist who specializes in studying the effects of psychedelic drugs on the brain.

Age of participants:

  • The study involved 24 people with major depression, with an average age of 45.


  • Participants were divided into two groups: a group that received a mushroom extract, and a group that received a placebo. The mushroom extract was administered orally at a dose of 300 mg per day for 4 weeks.


  • According to the results of the study, taking mushroom extract led to significant improvements in mood, sleep quality, and social activity among study participants. The group that received the mushroom extract had a 38% reduction in Beck Depression Inventory (BDI) scores compared to the group that received the placebo.


  • The study showed that mushroom extract may be an effective treatment for major depression. However, further research is needed to confirm these results and determine the optimal dose and duration of treatment.

For each client individually, we draw up instructions according to his indicators and requests

Monthly rate:

How to get discounts

Other articles on the topic:

  1. The chemistry of amanita and its effect on humans
  2. The effect of the mushroom (Amanita muscaria) on stress, anxiety and quality of life in people with chronic fatigue syndrome
  3. Improving sleep with fly agaric

Contact us: